januar 2020


Validé and Norwegian Smart Care Cluster cordially invite you to join us for an upcoming alternative asset class investment event specifically for the medical devices, digital health and diagnostics sector.

On January 21st, 2020, Validé and Norwegian Smart Care Cluster in collaboration with the USA Private Investment firm RQR Partners, will be evaluating a select group of Norwegian health innovations for private capital investment.

The leadership team of RQR Partners, https://rqrpartners.com/en/leadership, representing two large USA based family offices, has established a trusted relationship within the Norwegian innovation community, and is actively engaged identifying investment opportunities, and potential co investors. (RQR is in process of negotiating the term sheet with one Norwegian company and actively working on assessing the USA commercial opportunities with another Norwegian innovation).

With their executive leadership experience within the leading life science multi-national companies, they employ a proprietary method for identifying attractively valued assets for investment using their Commercial Viability Evaluation (CōVE) process, a Commercial Viability Event (CōVE). Using the commercial viewpoint of a life science corporate acquisition process and leveraging their extensive network within the industry, they deploy their private capital and operational expertise to facilitate early, predictable exits for the achievement of portfolio return targets.

Their team will be leading our selected participants through an extensive Commercial Viability workshop in Stavanger, and we welcome your attendance at both the private investor overview and afternoon workshops.

The event will take place in Måltidets Hus – Innovasjonsparken, with the following agenda:

10:00 – 11:30 Meet the investors

  •  Intro to RQR, the Commercial Viability investment model and investing in the ‘health’ market

11:30 – 12:30 Lunch 

12:30 – 14:00 - Live CōVE with one innovation

Real-time assessment with one pre-selected innovation of commercial viability and grant eligibility. For family offices and potential investors, this is a demonstration of RQR’s deep domain expertise and provides insight to the COMMERCIAL QUOTIENT® process to select investment assets. Topic covered are:

  • Strategic Acquisition
  • Value Proposition & Pricing
  • NIH Grant Eligibility
  • Clinical Viability

We hope you will find this interesting and that you/your company will join the event. Please register your attendance here.